A new method for screening acute/chronic lymphocytic leukemia: dual-label time-resolved fluorescence immunoassay
Tóm tắt
Lymphocytic leukemia (LL) is a primary malignant tumor of hematopoietic tissue, which seriously affects the health of children and the elderly. The study aims to establish a new detection method for screening acute/chronic LL using time-resolved fluorescence immunoassay (TRFIA) via quantitative detection of S100 calcium binding protein A8 (S100A8) and leucine-rich alpha-2-glycoprotein 1 (LRG1) in serum.
Here a sandwich TRFIA was optimized and established: Anti-S100A8/LRG1 caputre antibodies immobilized on 96-well plates captured S100A8/LRG1, and then banded together with the anti-S100A8/LRG1 detection antibodies labeled with Europium(III) (Eu3+)/samarium(III) (Sm3+) chelates. Finally time resolved fluorometry measured the fluorescence intensity.
The sensitivity of S100A8 was 1.15 ng/mL(LogY = 3.4027 + 0.4091 × LogX, R2 = 0.9828, P < 0.001, dynamic range: 2.1–10,000 ng/mL), and 3.2 ng/mL for LRG1 (LogY = 3.3009 + 0.4082 × LogX, R2 = 0.9748, P < 0.001, dynamic range: 4.0–10,000 ng/mL). The intra-assay and inter-assay CVs were low, ranging from 5.75% to 8.23% for S100A8 and 5.30% to 9.45% for LRG1 with high specificity and affinity in serum samples. Bland–Altman plots indicated TRFIA and ELISA kits have good agreement in clinical serum samples. Additionally, the cutoff values for S100A8 and LRG1 were 1849.18 ng/mL and 588.08 ng/mL, respectively. The present TRFIA method could be used for the quantitative detection of S100A8 and LRG1 in serum, and it has high sensitivity, accuracy and specificity. Clinically, this TRFIA method could be suitable for screening of LL via the quantitative detection of S100A8 and LRG1.
Tài liệu tham khảo
Cheung HM, Mok GCF, Lee V, et al. A Rare Presentation of Acute Lymphoblastic Leukaemia in a Teenage Girl: Heart Failure. Hong Kong J Paediatr. 2009;14(2):126–8.
Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381(9881):1943–55.
Doubek M, Brychtova Y, Panovska A, et al. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia results from a phase II study of the Czech leukemia study group for life. Blood. 2013;122(21):2877.
Yang M, Zeng P, Kang R, et al. S100A8 contributes to drug resistance by promoting autophagy in leukemia cells. PLoS One. 2014;9(5): e97242.
Yong HY, Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res. 2007;30(1):75–81.
Kim IS, Gu A, Lee JS. The role of S100A8 and S100A9 in differentiation of human eosinophilic leukemia Cells, EoL-1. Biomed Sci Lett. 2017;23:44–7.
Hu SY, Zhang MY, Wu SY, et al. High transcription levels Of S100A8 and S100A9 in acute myeloid leukemia are predictors for poor overall survival. Blood. 2013;122(21):2610.
Yang MH, Zeng P, Kang R, et al. S100A8 was elevated in drug resistance leukemia cells and chemotherapy agents induced S100A8 expression in leukemia cells. PLoS One. 2015. https://doi.org/10.1371/journal.pone.0097242.g001.
Alsagaby SA, Khanna S, Hart KW, et al. Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. J Proteome Res. 2014;13(11):5051–62.
Ouyang MF, Wang D, Liu YT, et al. Value of S100A8 in evaluating the prognosis of children with acute lymphoblastic leukemia. Chin J Contemp Pediatr. 2019;21:359–64.
Li X, Cheng F, Cao G. Expression of S100 calcium-binding protein A8 in peripheral blood of patients with preeclampsia during pregnancy. Eur J Inflamm. 2019;17(1):205873921985852.
Pepper RJ, Draibe JB, Caplin B, et al. Association of serum calprotectin (S100A8/A9) level with disease relapse in proteinase 3-antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2017;69(1):185–93.
Nambu M, Masuda T, Ito S, et al. Leucine-rich alpha-2-glycoprotein 1 in serum is a possible biomarker to predict response to preoperative chemoradiotherapy for esophageal cancer. Biol Pharm Bull. 2019;42(10):1766–71.
Weivoda S, Andersen JD, Skogen A, et al. ELISA for human serum leucine-rich alpha-2-glycoprotein-1 employing cytochrome c as the capturing ligand. J Immunol Methods. 2008;336(1):22–9.
Shinozaki E, Tanabe K, Akiyoshi T, et al. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. BMC Cancer. 2018;18(1):406–14.
Xiao S, Zhu H. Leucine-rich alpha-2-glycoprotein1 gene interferes with regulation of apoptosis in leukemia KASUMI-1 cells. Med Sci Monit. 2018;24:8348–56.
Yu RH. Serum proteomic and bioinformatic anaiysis in children with hematologic maiignancies. The first affiliated Hospital of Zhengzhou University. 2015
Lio DCS, Liu C, Wiraja C, Qiu B, Fhu CW, Wang X, Xu C. Molecular beacon gold nanosensors for leucine-rich alpha-2-glycoprotein-1 detection in pathological angiogenesis. ACS Sens. 2018;3(9):1647–55.
Yang X, Ye Y, Wang T, et al. Eu3+/Sm3+ dual-label time-resolved fluoroimmunoassay for measurement of hepatitis C virus antibodies. J Clin Lab Anal. 2019;33(2): e22659.
Maple PAC, Gray J, Breuer J, Kafatos G, Parker S, Brown D. Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and merck glycoprotein enzyme immunoassay. Clin Vaccine Immunol. 2006;13(2):214–8.
Hewamana S, Lin TT, Rowntree C, et al. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol. 2009;27(5):763–9.
Liu Y, Wang Y, Yang J, Bi Y, Wang H. ZAP-70 in chronic lymphocytic leukemia: a meta-analysis. Clin Chim Acta. 2018;483:82–8.
Liu Z, Huang J, Ou RM, et al. A dual-label time-resolved fluorescence immunoassay for the simultaneous determination of ferritin and β2 -microglobulin. J Clin Lab Anal. 2017. https://doi.org/10.1002/jcla.22132.
Liu Y, Liu YH, Bei WJ, et al. A dual-label time-resolved fluorescence immunoassay for the simultaneous determination of cystatin C and β2-microglobulin in urine. Br J Biomed Sci. 2017;74(4):193–7.
Zhang Z, Liu X, Li Y, et al. A dual-label time-resolved fluorescence immunoassay (TRFIA) for screening of Coronary atherosclerosis based on simultaneous detection of Lp-PLA2 and HsCRP. Immunol Lett. 2017;182:12–7.
Lin G, Chen S, Zhao H, et al. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency. Sci Rep. 2017;7(1):7288.
Li HT, Huang ZF, Lin BC, et al. Simultaneous detection of fungal (1,3)-β-D-glucan and procalcitonin using a dual-label time-resolved fluorescence immunoassay. Biotech Appl Biochem. 2021;68(1):157–64.